13 Novel Biomarkers in Assessing Outcome in Patients with Severe Aortic Stenosis and Heart Failure

Abstract

Introduction Severe Aortic stenosis (AS) and non-valvular heart failure (HF) appear to have different pathological processes, and therefore cardiac remodelling is likely to involve different pathways. Novel biomarkers have been developed to assess prognosis, response to treatment and also to understand the underlying mechanism of cardiac remodelling. We identified from the literature the biomarkers that have shown to demonstrate promise in assessing aortic stenosis and heart failure. We compared the differences in levels between the two groups and to see how they predict outcome (all-cause mortality). We identified biomarkers of fibrosis (ST2, galectin 3), matrix remodelling (osteopontin, PIIINP, TIMP1), stretch (NT-pro BNP, cardiotrophin/CTP). Methods We studied a total of 140 patients. 48 patients were recruited with chronic heart failure and EF